Skip To Main Content
Cameron Joseph on Muck Rack

Cameron Joseph

Verified
Washington, D.C.
As seen in: POLITICO, Apple News, MSN, MSN Ireland, MSN UK, The New York Times, Business Insider, Scribd, The Guardian, Yahoo Canada, Yahoo News and
Politics Editor @politico cjoseph@politico.com Almanac of American Politics sr. author Ex-@vicenews @nydailynews @csmonitor Bylines in @guardian @latimes @cjr

Get in touch with Cameron

Contact Cameron, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

COPD Treatment Landscape Expands, Yet Significant Gaps in Disease Control and Access Persist, According to Spherix Global Insights

|
By Cameron Joseph Verified
| spherixglobalinsights.com
Persistent access barriers leave many treatment candidates without advanced therapy as physicians look for stronger disease control and fewer exacerbations. EXTON, PA – September 8, 2026 – Despite recent treatment advances in chronic obstructive pulmonary disease (COPD), physicians continue to report substantial unmet need, particularly among patients with severe disease and a high risk of exacerbations.
Open in Who Shared View Duplicates (27) Issue with article?

‘Really alarming for some Republicans in competitive seats'

|
By Cameron Joseph Verified
| MSN Verified
The midterms are just two months away, and Republicans are growing more nervous. Polls show President Donald Trump is deeply unpopular with voters , and the battle for control of Congress continues to stretch into redder and redder territory. Democrats are feeling confident about their chances of retaking the House even as the GOP successfully redrew more seats to their advantage in the past year's controversial mid-decade redistricting fight..
Open in Who Shared View Duplicates (3) Issue with article?

Nearly two-thirds of Nephrologists Cite Limited Treatment Options as Alport Syndrome’s Greatest Challenge Amid Growing Pipeline Interest, According to Spherix Global Insights - Spherix Global Insights

|
By Cameron Joseph Verified
| spherixglobalinsights.com
Filspari and Vanrafia lead nephrologists’ most desired pipeline options as physicians seek therapies capable of improving renal outcomes beyond today’s supportive-care paradigm. EXTON, PA, August 31, 2026 – Despite a wave of new therapies reshaping treatment across rare and glomerular kidney diseases, Alport syndrome has largely been left behind. Among kidney diseases evaluated by Spherix Global Insights, nephrologists now rank Alport syndrome as having the greatest unmet need.
Open in Who Shared View Duplicates (28) Issue with article?
See all 2,833 licensed articles (3,758 Total)